Global Health Security Portfolio
"Today, we are announcing an innovative, cost-effective approach that puts us on a better path to take on the next public health crisis." – U.S. HHS Secretary Xavier Becerra
GHIC has partnered with BARDA to use venture capital investments to accelerate the development and introduction of technologies and medical products to respond to and prevent health security threats. Through this partnership, BARDA intends to provide GHIC with up to $500 million in funding over the course of the 10-year agreement to support the creation of a Global Health Security venture investment portfolio.
The Global Health Security portfolio is focused broadly on medical countermeasures that will better position the world to respond to or prevent public health emergencies, including vaccines, diagnostics, therapeutics, manufacturing platforms, and other critical technologies.
GHIC leverages its global health investment and commercialization experience while benefiting from BARDA’s scientific and technical input to help support important health security technologies. To amplify the impact of BARDA's funding, GHIC will mobilize additional capital from other investors for co-investment. As GHIC’s Global Health Security portfolio companies generate investment returns, proceeds from BARDA’s investment capital will be recycled by GHIC into additional investments. These investments will also be designed to advance the goals of the partnership, further amplifying the mission impact of BARDA’s initial funding.
Learn more about BARDA and BARDA Ventures here.
Portfolio Investments
Biolinq . Opens in new tab.
Global Health Security Portfolio
Intervention: Device
Targets: Diabetes, pre-diabetes, other diseases
Impact Objectives: Improve management of various clinical conditions and detect exposure to multiple public health agents
BugSeq Bioinformatics . Opens in new tab.
Global Health Security Portfolio
Intervention: Bioinformatics platform
Targets: Pathogen agnostic
Impact Objectives: Automated analysis of pathogen sequencing data for surveillance and pathogen agnostic diagnostic applications
Centivax . Opens in new tab.
Global Health Security Portfolio
Intervention: Vaccine platform
Targets: Influenza, COVID, other viruses
Impact Objectives: Universal protection against seasonal and pandemic viral threats
Endpoint Health . Opens in new tab.
Global Health Security Portfolio
Intervention: Therapeutic + Companion Diagnostic
Targets: Sepsis, autoimmune and inflammatory diseases
Impact Objectives: Apply a precision medicine approach to the treatment of sepsis, one of the leading causes of morbidity and mortality related to health security threats
Jumpcode Genomics . Opens in new tab.
Global Health Security Portfolio
Intervention: NGS sample prep
Targets: Pathogen agnostic
Impact Objectives: Next generation sequencing host depletion enabling pathogen agnostic surveillance and diagnostics
Micron Biomedical . Opens in new tab.
Global Health Security Portfolio
Intervention: Vaccine and drug delivery
Targets: Influenza and other viruses
Impact Objectives: Enable microneedle patch based delivery of health security vaccines and therapeutics
Monod Bio . Opens in new tab.
Global Health Security Portfolio
Intervention: Diagnostic
Targets: Critical healthcare and biotech applications
Impact Objectives: Create highly modular biosensors to develop rapid, sensitive, and cost-effective analytical assays
The Public Health Company . Opens in new tab.
Global Health Security Portfolio
Intervention: Data intelligence platform
Targets: Pathogen agnostic
Impact Objectives: Rapid identification, interpretation, and proactive response to evolving biosecurity threats
Resilience . Opens in new tab.
Global Health Security Portfolio
Intervention: Biomanufacturing
Targets: Biologics, vaccines, nucleic acids, and cell and gene therapies
Impact Objectives: Bolster pharmaceutical supply chain and support medical countermeasure development
Univercells . Opens in new tab.
Global Health Security Portfolio
Intervention: Biomanufacturing technology platform and CDMO
Targets: Viral vector vaccines, Gene therapies, mRNA
Impact Objectives: Improved access and reduced costs of essential biologics; distributed biomanufacturing
Vaxess Technologies . Opens in new tab.
Global Health Security Portfolio
Intervention: Vaccine delivery
Targets: Influenza and other viruses
Impact Objectives: Improve shelf stability and ease of administration with dissolvable microneedle patches for dermal vaccine and drug delivery
Undisclosed Company . Opens in new tab.
Global Health Security Portfolio
Intervention: Vaccine development